About Haley Chartres

This author has yet to write their bio.
Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 170 entries.

Entries by Haley Chartres

Investor Webinar Replay | 26 September 2023

Botanix (ASX: BOT) has received a communication from FDA in relation to its NDA submission for Sofpironium Bromide gel, 15% (SB) for the treatment of primary axillary hyperhidrosis. Encouragingly, no clinical efficacy, safety or manufacturing issues were raised and no additional clinical studies are required by the FDA to support approval. We will be revising […]

Bioshares Summit

Botanix is joining the biotech investment community at the 17th Bioshares Biotech Summit in Hobart this week. This year’s theme is ‘partnering and financing’, and Botanix Executive Director, Matt Callahan, will be sharing insights into the Company’s progress navigating towards FDA approval for Sofpironium Bromide. Click here to review the presentation.

A$12.5 million institutional placement

Botanix has announced it has secured firm commitments for A$12.5 million via an institutional placement. Proceeds from this raise will be used to extinguish future milestone and royalty payments linked to Botanix’s lead product, Sofpironium Bromide (SB) – in a move that could save up to $160 million and prime the Company for potential M&A […]

Video | Investor Webinar

Botanix (ASX: BOT) hosted a webinar recently to update investors on the Company’s progress during the FDA review period for its lead product, Sofpironium Bromide. The webinar was hosted by Executive Director, Matt Callahan and Chief Operating Officer, Howie McKibbon. Take a look.

New territory licensed for Sofpironium Bromide with partner Kaken

Botanix has today announced that our partner Kaken Pharmaceutical Co Ltd, has secured a new sublicense and distribution agreement for Sofpironium Bromide in Korea. The deal with Dong Wha Pharmaceuticals, Korea’s oldest pharmaceutical company, will see the expansion of Sofpironium Bromide into the Korean market. Sofpironium Bromide has been successfully marketed as ECCLOCK® by sublicensee […]

Investor Webinar Invitation

Botanix (ASX: BOT) is preparing to host an upcoming investor webinar on Wednesday 07/06/23, 10:30am AEST | 8:30am AWST. On this call, you will hear from Executive Director, Matt Callahan and Chief Operating Officer, Howie McKibbon. Together, they will be sharing an update on our progress during the current FDA-review stage for our lead product […]

Analyst Report | 6 April 2023

Euroz Hartleys has published an analyst note, reporting on the successful completion of Botanix’s FDA mid-cycle review meeting for Sofpironium Bromide, as well as the Company’s recent capital raise. Analyst Seth Lizée noted that $BOT remains considerably undervalued in comparison to its peers approaching an imminent FDA approval decision and soli data supporting commercial success. He wrote: […]

Botanix secures commitments for A $10 million via institutional placement

Botanix lifted a trading halt this morning, sharing news that it has secured commitments ofA$10.0million via institutional investors to accelerate the marketing and launch activities forSofpironium Bromide. Proceeds from the Placement will be used to progress Botanix’s lead developmentprogram, Sofpironium Bromide gel (15%), including costs associated with completingFDA review, manufacturing, satisfying milestone payments and preparing […]